🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

A quarter of symptomatic kids hit by long COVID; mRNA shots provide best protection in breast milk

Published 03/14/2022, 05:23 PM
Updated 03/14/2022, 05:26 PM
© Reuters. FILE PHOTO: Children are seen walking, on the first day of lifting the indoor mask mandate for DOE schools between K through 12, in Manhattan, New York City, New York, U.S., March 7, 2022. REUTERS/Andrew Kelly
JNJ
-
AZN
-
MRNA
-

By Nancy Lapid

(Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

One in four kids with COVID develop lingering problems

One in four children with COVID-19 symptoms develop "long COVID," according to data pooled from 21 earlier studies conducted in Europe, Asia, Australia and South America.

Among the 80,071 children with COVID-19 in the studies, 25% developed symptoms that lasted at least 4-to-12 weeks or new persistent symptoms that appeared within 12 weeks, researchers reported on Sunday on medRxiv ahead of peer review.

The most frequent problems were neuropsychiatric (mood symptoms, fatigue, sleep disorders, headaches, cognitive alterations, dizziness, balance problems), cardiorespiratory (breathing difficulty, congestion, exercise intolerance, chest pain and tightness, cough, irregular heart rhythm), skin-related (excessive sweating, itchiness, hair loss) and gastrointestinal (abdominal pain, constipation, diarrhea, vomiting, and nausea). Analyses of data pooled from many different studies with different methodologies cannot yield firm conclusions, the researchers acknowledge. What is clear, however, is that "children and adolescents have also physical and mental health consequences derived from COVID-19," said study coauthor Sonia Villapol of Houston Methodist Research Institute in Texas.

"Identifying the main signs and symptoms of pediatric long COVID can help diagnose, develop better treatments, create multidisciplinary teams for optimal clinical management, and find risk factors for prevention."

Vaccine protection in mother's milk strongest after mRNA shots

Women who wish to pass protective antibodies induced by COVID-19 vaccines to their babies via breast milk should opt for the mRNA shots from Moderna (NASDAQ:MRNA) or Pfizer/BioNTech, according to a study reported on Monday in JAMA Pediatrics.

For the study, 124 lactating women each provided 17 milk samples over a period of 100 days.

The women had received either an mRNA vaccine or a vector-based vaccine from Johnson & Johnson (NYSE:JNJ) or AstraZeneca (NASDAQ:AZN). Researchers measured two types of antibodies in the milk samples - IgA antibodies and IgG antibodies, both of which are thought to play important roles in protecting breastfed infants. Nearly all - 96% to 97% - of the women who received both doses of an mRNA vaccine had detectable IgA antibodies in their milk, while only 39% had antibodies in their milk after two doses of the AstraZeneca shot and 48% after the one-dose J&J vaccine. All the women who received both doses of the Pfizer/BioNTech, Moderna or AstraZeneca vaccines had IgG antibodies, compared to only 28% of women who received J&J's shot.

"An mRNA-based COVID-19 vaccine is the optimal choice for lactating women when they want to transfer breast milk antibodies to their infants," the researchers concluded.

Omicron is infectious on surfaces longer than original virus

Omicron particles remain infectious on surfaces for longer periods than particles of the original SARS-CoV-2, according to laboratory experiments.

Researchers put droplets of infectious virus from the original coronavirus version and the Omicron BA.1 variant on a variety of surfaces at room temperature.

On smooth surfaces (glass, stainless steel and plastic sheet), Omicron was still infectious after seven days, whereas particles of the original SARS-CoV-2 were no longer infectious on stainless steel and plastic sheets by day 4 and on glass by day 7, the researchers reported on Thursday on bioRxiv ahead of peer review.

© Reuters. FILE PHOTO: Children are seen walking, on the first day of lifting the indoor mask mandate for DOE schools between K through 12, in Manhattan, New York City, New York, U.S., March 7, 2022. REUTERS/Andrew Kelly

On tissue paper and printing paper, the original virus was no longer infectious at 30 minutes. Omicron was still infectious at 30 minutes, but no longer after an hour, the researchers said.

For the most part, SARS-CoV-2 is transmitted via respiratory droplets in the air. While infection via contact with contaminated surfaces is less common, the new study "highlights the importance of hand hygiene and cleaning on surfaces that are regularly touched by different persons," said study coauthor Leo Poon of the University of Hong Kong. "For surfaces and settings contaminated by a COVID-19 patient, proper cleaning should be done."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.